Matthew J. D'Onofrio - 28 Jan 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role: Chief Executive Officer, Director
Signature: /s/ Matthew J. D'Onofrio
Issuer symbol: EVOK
Transactions as of: 28 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 29 Jan 2025, 16:30:10 UTC
Previous filing: 08 Aug 2024
Next filing: 03 Mar 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVOK	Stock Option (Right to Buy)	Award	$0	+70,000		$0.000000	70,000	28 Jan 2025	Common Stock	70,000	$4.45	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-third of the total number of shares subject to the option shall vest on the 12 month anniversary of January 28, 2025, and one-thirty-sixth of the other two-thirds of the total number of shares subject to the options shall vest on each monthly anniversary of the Vesting Commencement Date thereafter, subject to continuous service to the Company on each such vesting date, so that the options shall be fully vested on the third anniversary of the Vesting Commencement Date.

Content

One-third of the total number of shares subject to the option shall vest on the 12 month anniversary of January 28, 2025, and one-thirty-sixth of the other two-thirds of the total number of shares subject to the options shall vest on each monthly anniversary of the Vesting Commencement Date thereafter, subject to continuous service to the Company on each such vesting date, so that the options shall be fully vested on the third anniversary of the Vesting Commencement Date.